Vertex Pharmaceuticals

VRTX · NASDAQ · USD

$504.73−0.40%−$2.01

Close · October 2, 2026

At a glance

Revenue growth
+8.90%
2025 vs 2024
Net margin
32.9%
2024: -4.9%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets27,42326,48425,64324,86224,03722,88122,53322,24020,13223,91722,73021,726
Current assets12,54411,73011,20110,57010,42810,0099,5969,8048,94213,28914,14414,696
Cash and equivalents6,1445,4935,0854,9404,9724,6754,5705,2394,5809,15810,36911,110
Short-term investments1,7091,7541,5231,3471,4111,5271,5461,2851,2151,013849818
Receivables2,1341,9962,0531,9461,8941,8051,6091,7511,6561,7931,5631,539
Inventory1,7651,7671,6871,6271,4991,3601,2051,080915813739689
Net property, plant and equipment3,3283,2943,0833,0172,6492,6342,5852,5141,7711,4861,4531,435
Goodwill1,0881,0881,0881,0881,0881,0881,0881,0881,0881,0881,0881,088
Other intangible assets413419424430436441826832838835840604
Long-term investments5,8695,8315,7945,8045,7125,2215,1734,7784,4784,4562,4981,799
Current liabilities3,9383,8813,8614,4754,1383,7833,5653,9733,5473,7963,5473,599
Accounts payable430489462420442445413396328351365376
Total debt1,9781,9872,0361,8351,5271,6491,7501,774933721——
Total liabilities7,1757,1236,9777,5446,8616,3846,1246,6095,3575,3715,1505,213
Total equity (incl. minority)20,24819,36218,66617,31917,17516,49616,41015,63114,77518,54717,58016,513
Retained earnings15,69114,59113,56012,36911,28610,2539,6078,6947,64811,24210,1429,174